Research and Development

Dual immunotherapy, a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), has been granted extension in the UK by the Medicines …

Effective from September 2025, AOTI’s Topical Wound Oxygen (TWO2) therapy has been awarded inclusion in the NHS supply chain. It …

Galapagos NV has announced key leadership changes as it prepares to separate into two independent entities. Henry Gosebruch has been …

Allegro’s hydrocelin treatment for osteoarthritis has demonstrated a satisfactory safety profile, giving it potential to become a leading disease-modifying treatment …

Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed significantly longer progression-free survival (PFS) …

ProQR Therapeutics announced two major leadership appointments to support its transition into the clinical development phase of its RNA editing …

Eyestem Research, an Indian biotech company, announced successful results from its phase 1 trial of Eyecyte-RPE, a potential therapy for …

International pharma company Nordic Pharma has announced that its Lacrifill treatment for dry eye disease has received European Conformity (CE) …

UK-based clinical trials company, Richmond Pharmacology, has completed the first stage of Velora Pioneer, a phase 1/2 clinical trial investigating …

Dutch diagnostics firm Inbiome has received In Vitro Diagnostic Regulation (IVDR) certification from the EU for its Molecular Culture ID …

AAX Biotech has appointed Ionut Gabriel Dumitru (pictured left) as senior scientist and Kushal Sejwal (pictured right) as business developer, …

TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the progression of Alzheimer’s disease over …

The cancer biotech company Infinitopes has gained approval by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to evaluate …

The Scottish Medicines Consortium (SMC) has accepted the use of Ipsen’s Iqirvo (elafibranor) in NHS Scotland for the treatment of …

High Force Research has announced that it has appointed Nathalie Huther as its first chief commercial officer (CCO) following the …